Company Long-Term Loans and Borrowings: Marinus (MRNS)

Brandmark of Marinus (MRNS)

Marinus Pharmaceuticals (MRNS) maintains a high reputation among physicians due to the development of safe Ganaxolone for treating pediatric seizures. The specifics of addressing rare pathologies make the business crisis-resistant, as demand for therapy is independent of GDP. This trading chart captures the 0.00 metric. The company is currently scaling ZTALMY sales and implementing new treatment programs for neurological disorders.

Marinus Pharmaceuticals, Inc. (MRNS) Company Long-Term Debt: for the period 07/04/2022 - 02/22/2025

Summary analytical data breakdowns for Marinus (MRNS)

- market price and analyst price targets:
Stock Price marinuspharma.com|MRNS - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Marinus Pharmaceuticals|MRNS - Total Company Value
- book capitalization information:
Net Asset Value per Share Marinus Pharmaceuticals|MRNS - Company Book Value|Market Cap to Net Assets Ratio marinuspharma.com|MRNS - Company Total Assets
- debt level and financial liquidity data:
Total Debt to Capital Marinus Pharmaceuticals|MRNS - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Marinus Pharma|MRNS - Company Aggregate Debts|Debts to Net Assets Marinus Pharmaceuticals|MRNS - Company Long-Term Debt|Company Short-Term Indebtedness Marinus Pharmaceuticals|Quick Ratio marinuspharma.com
- earnings and market multiples details:
MRNS - Company Net Income
Summary company analytics:MRNS marinuspharma.com
Original product of Marinus Pharma

Long-term debt represents the aggregate of all organizational liabilities with a maturity exceeding twelve months. This metric measures financial leverage, assessing the company's ability to service capital expenditures without the risk of an immediate loss of liquidity. By analyzing the firm's history of long-term borrowings, an investor determines the business's degree of dependence on external financing. For Marinus Pharmaceuticals (MRNS), this indicator reflects the cost of expanding its anti-epilepsy drugs. Growth in cash flows following the commercialization of medications allows the company to optimize its debt load.

Competitors of Marinus Pharmaceuticals (MRNS)

Company Long-Term Debts biogen.com BIIB|NBIX - Company Long-Term Debt|Company Long-Term Loans and Borrowings RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc (AXSM) - Company Long-Term Debt|Long-Term Debt ACADIA Corp (ACAD)|Company Long-Term Debt Xenon Pharmaceuticals|Company Long-Term Liabilities vikingtherapeutics.com (VKTX)|Company Long-Term Debts SUPN|Company Long-Term Debts Catalyst Pharma (CPRX)|Company Long-Term Debt Denali Therapeutics Inc DNLI|Company Long-Term Loans and Borrowings HRMY|Biohaven Ltd. - Company Long-Term Debts|Long-Term Debt Volume amylyx.com AMLX|Trevi Therapeutics, Inc. (TRVI) - Company Long-Term Debt|Company Long-Term Indebtedness PRAX|Company Long-Term Liabilities AVXL|Company Long-Term Debts CeriBell EEG|Company Long-Term Debt Prothena (PRTA)|Long-Term Debt Volume alector.com|Annexon - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings OMER|NGNE - Company Long-Term Debt|Long-Term Liabilities ACIU|VYGR: Company Long-Term Debts|neumoratx.com - Company Long-Term Loans and Borrowings|SCLX (Scilex) - Company Long-Term Debts|Company Long-Term Debts Tevogen Bio Holdings Inc.|Company Long-Term Debt Alpha Cognition (ACOG)|CGTX (cogrx.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Inhibikase Therapeutics IKT|SAVA - Company Long-Term Liabilities|Assertio Therapeutics - Company Long-Term Debts|COYA - Company Long-Term Debts|VTGN: Company Long-Term Debts|Company Long-Term Liabilities Ovid Therapeutics|ABOS (Acumen Pharmaceuticals) - Company Long-Term Debts|Long-Term Debt cervomed.com CRVO|Company Long-Term Liabilities ATHE (Alterity Therapeutics)|Company Long-Term Debts clene.com (CLNN)|PepGen - Company Long-Term Liabilities|Amount of Long-Term Liabilities JUNS (jupiterneurosciences.com)|Relmada Therapeutics - Company Long-Term Debts|Long-Term Debt Volume annovisbio.com ANVS|GRCE: Company Long-Term Debts|Company Long-Term Liabilities Firefly Neuroscience, Inc.|KLTO (ANEW Medical) - Company Long-Term Debts|Company Long-Term Debts NeuroSense Therapeutics, Ltd.|Company Long-Term Debt Reviva Pharmaceuticals (RVPH)|Company Long-Term Debt MTVA (metaviatx.com)|Company Long-Term Debt NeurAxis NRXS|Long-Term Debt Volume Helius Medical Technologies, Inc. (HSDT)|PASG - Company Long-Term Debt|Neuphoria Therapeutics Inc. (NEUP) - Company Long-Term Liabilities|Minerva Neurosciences (NERV) - Company Long-Term Debt|athira.com - Company Long-Term Loans and Borrowings|Company Long-Term Debt Addex Therapeutics Ltd|Company Long-Term Indebtedness ALZN (Alzamend)|Company Long-Term Debt Cyclerion Therapeutics (CYCN)|Long-Term Debt Volume protagenic.com|Company Long-Term Debt Pasithea Therapeutics Corp. KTTA|CRGT: Company Long-Term Indebtedness|Avenue Therapeutics, Inc. - Company Long-Term Debts|Long-Term Debt Brainstorm Cell Therapeutics Inc.|CARA (Cara Therapeutics, Inc) - Company Long-Term Liabilities|Chromocell (CHRO) - Company Long-Term Debts|Company Long-Term Debt Eliem Therapeutics, Inc.|ITCI: Company Long-Term Loans and Borrowings|Company Long-Term Debt Longboard Pharmaceuticals, Inc. (LBPH)|NKGN - Long-Term Debt|Company Long-Term Debt NeuroBo NRBO|SAGE - Company Long-Term Liabilities|Synaptogenix, Inc. - Company Long-Term Debts|TRVN - Company Long-Term Debts|vigilneuro.com (VIGL) - Company Long-Term Debt|Anew Medical Inc. - Company Long-Term Loans and Borrowings|CERE (Cerevel) - Company Long-Term Debts